Investor Relations Home

Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Accuray does not assume a duty to update information on this website, except through the normal quarterly financial press releases and regulatory filings.

ARAY (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.05 (1.12%)
Data as of Jul 26, 2017 10:06 a.m. ET
Refresh quote
Stock chart for: ARAY.O.  Currently trading at $4.50 with a 52 week high of $6.39 and a 52 week low of $3.85.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function ... 
Jul 20, 2017
Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results
Q4 Revenue Expected to be Approximately $111.5-$112 Million and Q4 Gross Orders Expected to be Approximately $86 Million; Accuray Expects to Finish Fiscal Year with Approximately $108 Million in Cash, Cash Equivalents & Investments Preliminary... 
Jul 17, 2017

Upcoming Investor Event

There are currently no events scheduled.
Some documents in the Investor Relations section require that you have Adobe Acrobat Reader® installed in order to view files in PDF format. Download the newest version of Acrobat Reader